Zeynep Yüce

Zeynep Yüce

Auto-generated profile, based on publicly available information

Zeynep Yüce

Dokuz Eylül Üniversitesi

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SBSeda Baykal-Köse
Seda Baykal-Köse
EAEda Acikgoz
Eda Acikgoz
AYAhmet Sinan Yavuz
Ahmet Sinan Yavuz
ÖGÖykü Gönül Geyik
Öykü Gönül Geyik
HAHalil Ateş
Halil Ateş
ZYZeynep Yüce
Zeynep Yüce
Tyrosine kinase inhibitor (TKI) resistance is a major problem in chronic myeloid leukemia (CML). We generated a TKI-resistant K562 sub-population, K562-IR, under selective imatinib-mesylate pressure. K562-IR cells are CD34-/CD38-, BCR-Abl-independent, proliferate slowly, highly adherent and form intact tumor spheroids. Loss of CD45 and other hematopoietic markers reveal these cells have diverged from their hematopoietic origin. CD34 negativity, high expression of E-cadherin and CD44; decreased levels of CD45 and β-catenin do not fully confer with the leukemic stem cell (LSC) phenotype. Expression analyses reveal that K562-IR cells differentially express tissue/organ development and differentiation genes. Our data suggest that the observed phenotypic shift is an adaptive process rendering cells under TKI stress to become oncogene independent. Cells develop transcriptional instability in search for a gene expression framework suitable for new environmental stresses, resulting in an adaptive phenotypic shift in which some cells partially display LSC-like properties. With leukemic/cancer stem cell targeted therapies underway, the difference between treating an entity and a spectrum of dynamic cellular states will have conclusive effects on the outcome.

4 August 2020 in Turkish Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
TRTrëndelina Rrustemi
Trëndelina Rrustemi
ÖGÖykü Gönül Geyik
Öykü Gönül Geyik
AÖAli Burak Özkaya
Ali Burak Özkaya
TÖTaylan Kurtuluş Öztürk
Taylan Kurtuluş Öztürk
ZYZeynep Yüce
Zeynep Yüce
AKAli Kılınç
Ali Kılınç
Objectives: Cancer cells modulate metabolic pathways to ensure continuity of energy, macromolecules and redox- homeostasis. Although these vulnerabilities are often targeted individually, targeting all with an enzyme may prove a novel approach. However, therapeutic enzymes are prone to proteolytic degradation and neutralizing antibodies leading to a reduced half-life and effectiveness. We hypothesized that glucose oxidase (GOX) enzyme that catalyzes oxidation of glucose and production of hydrogen peroxide, may hit all these targets by depleting glucose; crippling anabolic pathways and producing reactive oxygen species (ROS); unbalancing redox homeostasis. Methods: We encapsulated GOX in an acrylamide layer and then performed activity assays in denaturizing settings to determine protection provided by encapsulation. Afterwards, we tested the effects of encapsulated (enGOX) and free (fGOX) enzyme on MCF-7 breast cancer cells. Results: GOX preserved 70% of its activity following encapsulation. When fGOX and enGOX treated with guanidinium chloride, fGOX lost approximately 72% of its activity, while enGOX only lost 30%. Both forms demonstrated remarkable resilience against degradation by proteinase K and inhibited viability of MCF-7 cells in an activity-dependent manner. Conclusions: Encapsulation provided protection to GOX against denaturation without reducing its activity, which would prolong half-life of the enzyme when administered intravenously.

1 June 2018 in Leukemia Research
Verified
Journal Article
Closed access
MPMelek Pehlivan
Melek Pehlivan
CÇCeyda Çalışkan
Ceyda Çalışkan
ZYZeynep Yüce
Zeynep Yüce
HSHakki Ogun Sercan
Hakki Ogun Sercan

1 April 2022 in Anti-Cancer Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MPMelek Pehlivan
Melek Pehlivan
CCCeyda Caliskan
Ceyda Caliskan
ZYZeynep Yuce
Zeynep Yuce
HSHakki O. Sercan
Hakki O. Sercan
Background: Wnt signaling cascades play important roles in cell fate decisions and their deregulation has been documented in many diseases, including malignant tumors and leukemia. One mechanism of aberrant Wnt signaling is the silencing of Wnt inhibitors through epigenetic mechanisms. The sFRPs are one of the most studied Wnt inhibitors; and the sFRP1 loss is known in many hematological malignancies. Therefore, we aimed to compare the expression of Wnt related genes in the presence and absence of sFRP1 in a chronic myeloid leukemia (CML) cell line. Objective: It is important to understand how sFRP1 and sFRP1 perform their effects on CML to design new agents and strategies for resistant and advanced forms of CML. Materials and Methods: We used K562 cells, which normally do not express sFRP1 and its sFRP1 expressing subclone K562s. Total RNA was isolated from K562 and K562s cell lines and converted to cDNA. PCR Array experiments were performed using Human Wnt Signaling Pathway Plus RT2 Profiler™ kit. Wnt signaling pathway activation was studied by western blot for downstream signaling targets. Results: The WNT3, LRP6, PRICKLE1 and BTRC expressions were significantly decreased in the presence of sFRP1; while WNT5B increased. The sFRP1 expression inhibited stabilization of total β-catenin protein and downstream effector phosphorylation of noncanonical Wnt/PCP signaling; whereas Ca2+/PKC signaling remained active. Conclusion: The results suggest that sFRP1 could be a promising therapeutic anticancer agent. Defining these pathway interactions is crucial for designing new agents resistant and advanced forms of CML.

27 May 2021 in Journal of Basic and Clinical Health Sciences
Verified
Journal Article
Closed access
ÖYÖzge Uysal Yoca
Özge Uysal Yoca
HEHande Efe
Hande Efe
ZYZeynep Yüce
Zeynep Yüce
Life gave rise on our planet 3-4 billion years ago and since then, living organisms (from one cell to multicellular organisms) have undergone many genetic, phenotypic and communal changes. Scientists have been able to shed light on only a small part of this evolutionary process, but with the development of new techniques our knowledge is expanding day by day. For the past 30 years ancient DNA studies have aided us in understanding the molecular basis of the changes observed in living organisms. Ancient DNA (aDNA) is the genetic material obtained from biological remains (bones, teeth, plant seeds, etc.) acquired from archaeological and paleontological excavations. In the present review, molecular studies carried out to date, contributions of ancient DNA to medical sciences, as well as basic problems encountered in obtaining and using aDNA have been discussed.

11 October 2024 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
SBSeda Baykal
Seda Baykal
ZYZeynep Yuce
Zeynep Yuce
Gunes OzhanGunes Ozhan
Gunes Ozhan
Understanding the mechanisms by which cancer cells switch between different adaptive states and evade therapeutic interventions is essential for clinical management. In this study, the in vivo cellular dynamics of a new chronic myeloid leukaemia cell line displaying altered phenotype and resistance to tyrosine kinase inhibitors were investigated in correlation with their parental cells for invasiveness/metastasis, angiogenic potential and population kinetics. We showed that the cells exhibiting drug resistance and plastic phenotype possess an increased capacity for invasion compared to their parental cells, that exposure to imatinib mesylate has the potential to enhance cellular motility and that in a leukaemic cell population, even a minority of plastic cells exhibit improved migratory ability. Furthermore, we show that these plastic cells have angiogenic and extravasation potential. The present study provides significant insights into the cellular dynamics displayed by a TKI‐resistant, phenotypically plastic CML cell line, using a zebrafish (Danio rerio) xenograft model.